Versartis to Present at the Canaccord Genuity Growth Conference
August 02 2017 - 8:30AM
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused
biopharmaceutical company that is developing somavaratan, a novel,
long-acting form of recombinant human growth hormone (rhGH) for
growth hormone deficiency (GHD), today announced that Jay Shepard,
President and CEO, is scheduled to present at the Canaccord Genuity
37th Annual Growth Conference on Wednesday, August 9, 2017 at the
InterContinental Boston.
Event: Canaccord Genuity 37th Annual Growth
ConferenceDate: Wednesday, August 9,
2017Time: 10:30 a.m. ET / 7:30 a.m.
PTLocation: InterContinental Boston – Boston,
MA
An audio webcast of the Company's presentation will be available
on the investor relations section of the Versartis website at
www.versartis.com. A replay of the presentation will be available
for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical
company initially developing somavaratan, a novel, long-acting form
of recombinant human growth hormone in late-stage clinical trials
for the treatment of GHD in children and adults. Somavaratan is
intended to reduce the burden of daily injection therapy by
requiring significantly fewer injections, potentially improving
adherence and, therefore, treatment outcomes.
For more information on Versartis, visit www.versartis.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, plans and timing of our clinical
trials and the potential for eventual regulatory approval of
somavaratan. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated. We discuss many of these risks in greater detail
under the heading "Risk Factors" contained in our Annual Report on
Form 10-K for the year ended December 31, 2016 and in our
Quarterly Report on Form 10-Q for the three months ended March 31,
2017 which are on file with the Securities and Exchange
Commission (SEC). Forward-looking statements are not
guarantees of future performance, and our actual results may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release and
we assume no obligation to update them after the date of this press
release.
Contacts:
Corporate Communications:
Christine Labaree
Corporate Affairs
(650) 600-1697
clabaree@versartis.com
Investors:
David Burke
Director, Investor Relations
(650) 516-2703
dburke@versartis.com
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Apr 2023 to Apr 2024